Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | GHSR | Q92847 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | FURIN | P09958 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 2/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30167978 | 0.97 | PTPN1 (0.46) | PTPN1OPRM1OPRD1ATMCTSL | |
| SCHEMBL30100119 | 0.93 | FPR2 (0.50) | FPR2MMP3 | |
| SCHEMBL30990575 | 0.86 | CCKBR (0.49) | PTPN1 | |
| SCHEMBL30167976 | 0.84 | MMP1 (0.48) | PTPN1OPRM1OPRD1ATMFPR2 | |
| SCHEMBL7603846 | 0.83 | KIF11 (0.50) | PRSS1PRSS2PRSS3FPR2 | |
| SCHEMBL17274480 | 0.83 | KIF11 (0.50) | PRSS1PRSS2PRSS3FPR2 | |
| SCHEMBL20964465 | 0.80 | PRSS1 (0.54) | PTPN1PRSS1PRSS2PRSS3CTSL | |
| SCHEMBL26439541 | 0.78 | GHSR (0.53) | GHSRCTSLFURINMMP1MMP3 | |
| SCHEMBL29965298 | 0.78 | OPRD1 (0.49) | PTPN1OPRM1OPRD1 | |
| SCHEMBL29964895 | 0.76 | MMP3 (0.44) | MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548913-B2 | Therapeutic compositions including peptides and uses thereof | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-01-10 | — | — | US | claimed |
| US-11548913-B2 | Therapeutic compositions including peptides and uses thereof | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548913-B2 | Therapeutic compositions including peptides and uses thereof | VIP, IAPP, TNNI3 | PTPN1 1541/4885OPRM1 2534/4885OPRD1 3399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.